FDA Grants Breakthrough Therapy Designation to Elsunersen for SCN2A Epilepsy
A 77% sham-adjusted reduction in monthly seizures from a nine-patient Phase 1/2 trial is an extraordinary signal for any rare pediatric epilepsy program, and the FDA has now formalized its view of that data by granting…
Read more